[
  {
    "chunk_id": 0,
    "text": "Renal disease THEME Chronic kidney disease Management update C hronic kidney disease (chronic kidney disease) is defined as a glomerular BACKGROUND Chronic kidney disease (chronic kidney disease), defined as a glomerular filtration rate less than filtration rate (glomerular filtration rate) less than 60 milliliters per minute/1. 73 m2 and/or 60 milliliters per minute/1. 73 m2 and/or evidence of kidney evidence of kidney damage for a period of at least 3 damage for a period of at least 3 months, is months (Table 1). Glomerular filtration rate can either be an increasingly common, serious and undermeasured directly (eg. by clearance of creatinine, iohexol, recognised condition. A recent population study European Dialysis and Transplant Association, diethylenetriamine pentaacetic acid scan or iothalamate) or estimated by a validated David W Johnson demonstrated that one in every 6 Australian prediction formula (eg. Cockcroft-Gault or Modification MBBS, FRACP, PhD, is adults has chronic kidney disease (of which the vast majority are of Diet in Renal Disease MDRD equations). 1 Director of Nephrology, Professor of Medicine, unaware). Evidence of kidney damage includes microalbuminuria, University of OBJECTIVE This article aims to provide timely macroalbuminuria, persistent haematuria (where other Queensland at Princess Alexandra Hospital, information to health professionals about how to causes such as urologic conditions have been excluded), Brisbane, Queensland. classify and manage chronic kidney disease. or radiological abnormalities (eg. the presence of david_johnsonhealth. DISCUSSION Management of chronic kidney disease involves scarring or polycystic kidneys on a renal ultrasound qld. gov. au regular monitoring of cardiovascular and renal scan). Chronic kidney disease is classified into five risk factors, identifying and treating common stages according to the glomerular filtration rate level (Table 2). Tim Usherwood chronic kidney disease complications, and avoiding medications Chronic kidney disease is a major public health MD, FRACGP, FRCP, is that may worsen chronic kidney disease. Early detection and timely problem in Australia and throughout the world. Based Professor of General Practice, University of appropriate management of chronic kidney disease (especially on data from the Ausdiab study, 2 it is estimated that Sydney at Westmead with respect to blood pressure control) will over 2. 3 million Australian adults have at least one Hospital, Sydney, New substantially reduce kidney failure progression manifestation of chronic kidney disease (Table 1). This includes over 1. 4 South Wales. and cardiovascular risk by up to 50%. million individuals with at least moderate kidney failure (defined as a glomerular filtration rate 60 milliliters per minute/1. 73m2), 800 000 with microalbuminuria, 80 000 with macroalbuminuria and 600 000 with persistent haematuria. Moreover, approximately 6 million individuals have at least one of the major risk factors for chronic kidney disease (Table 3). Chronic kidney disease is often not associated with significant symptoms and is unrecognised in 8090% of cases. 24 The role of the GP With over 1. 7 million adults with stage 3 chronic kidney disease (glomerular filtration rate 3060 milliliters per minute) and only 180 nephrologists in Australia, it is clear that the majority of chronic kidney disease patients (stages 1, 2 and 3) will be managed primarily by Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 4 915 Theme: Chronic kidney disease management update general practitioners (Table 4). Principal goals of chronic kidney disease Reduction of cardiovascular and renal risk management are: in chronic kidney disease reduction of cardiovascular and renal risk All patients with chronic kidney disease should undergo cardiovascular early detection and management of chronic kidney disease and kidney disease risk factor modification.",
    "word_count": 578,
    "char_count": 3955,
    "sentence_count": 32,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 0,
      "total_chunks": 11,
      "position": "1/11",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "creatinine",
        "diet",
        "dialysis",
        "blood pressure control",
        "monitoring",
        "stage 3"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 1,
    "text": "5, 6 The complications presence of chronic kidney disease is one of the most potent known avoidance of nephrotoxic medications and ensuring risk factors for cardiovascular disease7, 8 such that that dosages of other prescribed drugs are individuals with chronic kidney disease have a 1020 fold greater risk appropriate for the level of kidney function, and of cardiac death than age and sex matched controls timely referral of chronic kidney disease patients to a nephrologist. without chronic kidney disease. 9 Moreover, patients with chronic kidney disease are at least 20 times more likely to die from cardiovascular Table 1. Definition of chronic kidney disease disease than survive to reach dialysis. 10 There is strong randomised controlled trial evidence that timely glomerular filtration rate 60 milliliters per minute/1. 73 m2 for ≥3 months with or without evidence of intervention in this group of patients can substantially kidney damage, OR reduce kidney failure progression and cardiovascular Evidence of kidney damage (with or without decreased glomerular filtration rate) for ≥3 risk by up to 50%. 11 Once glomerular filtration rate is substantially months, as evidenced by any of the following: reduced (≤60 milliliters per minute/1. 73 m2), the natural history is a microalbuminuria (urinary albumin excretion rate 30300 magnesium/day) continuing decline. The steps outlined below will slow macroalbuminuria (urinary albumin excretion rate 300 magnesium/day) the decline, but regular monitoring (at least every 3 persistent haematuria (where other causes such as urologic conditions have been excluded) months) is essential. pathologic abnormalities (eg. abnormal renal biopsy) Blood pressure reduction radiologic abnormalities (eg. scarring or polycystic kidneys on renal ultrasound scan) The most important goal in patients with chronic kidney disease is to reduce arterial blood pressure to target levels Methods for measuring or calculating GFR1 (130/85 mmHg if proteinuria 1 g/day or 125/75 mmHg if proteinuria 1 g/day or diabetic). 12 In order to Table 2. Stages of chronic kidney disease (based on the CARI guidelines12) reach currently recommended blood pressure targets, multiple (often 34) antihypertensive medications are frequently required. 11 Meta-regression analyses1316 Stage Description glomerular filtration rate Prevalence Numbers in (milliliters per minute/1. 73 m2) from AusDiab2 Australia have indicated that blood pressure reduction 1 Kidney damagea with ≥90 3. 1% 400 000 accounts for 50% of the variance in glomerular filtration rate decline normal or and that each 10 mmHg reduction in mean arterial pressure (down to 92 mmHg) confers a benefit in glomerular filtration rate preservation of 3. 75. 0 milliliters per minute/year. Based on the weight of accumulated evidence to date, angiotensin converting enzyme (ACE) inhibitors remain the first line therapy for patients with chronic kidney disease, 17 although recent new evidence in type 2 diabetic nephropathy suggests that angiotensin receptor blockers (angiotensin receptor blocker) may provide comparable renoprotection. 1820 Antiproteinuric agents The benefits of ACE inhibitors and angiotensin receptor blocker seem to be disproportionate to the degree of blood pressure reduction16, 18, 2123 and proportional to the degree of baseline proteinuria2426 and its reduction following treatment. 18, 24 Several studies have found that ACE inhibitors and angiotensin receptor blocker are more effective than other specific antihypertensive agents, including diuretics, ß-blockers and calcium channel blockers, in reducing protein excretion and in slowing the decline of kidney 916 3Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 glomerular filtration rate 2 Kidney dama gea with 6089 4% 500 000 mild glomerular filtration rate 3 Moderate glomerular filtration rate 3059 10. 9% 1 400 000 4 Severe glomerular filtration rate 1529 0. 3% 40 000 5 Kidney failure 15 or on dialysis 0.",
    "word_count": 592,
    "char_count": 4001,
    "sentence_count": 26,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 1,
      "total_chunks": 11,
      "position": "2/11",
      "content_type": "treatment",
      "content_type_confidence": 9,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "nephropathy",
        "proteinuria",
        "calcium",
        "magnesium",
        "ACE inhibitors",
        "angiotensin receptor blockers"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 2,
    "text": "3% 40 000 5 Kidney failure 15 or on dialysis 0. 02% 13 200 a kidney damage is defined as persistent microalbuminuria, persistent proteinuria, persistent haematuria after exclusion of urological causes, or structural abnormalities on kidney imaging tests Table 3. Major risk factors for chronic kidney disease24 Percentage of Australian population affected Hypertension 29 Diabetes mellitus 7. 5 Age over 50 years 30 Smoking 16 Aboriginal or Torres Strait Islander 2 Theme: Chronic kidney disease management update function. 16, 2729 The degree of renoprotection afforded nephropathy in patients with type 1 diabetes also appears to be greater in patients with more mellitus50, 51 and type 2 diabetes mellitus. 52, 53 Based severe degrees of kidney failure14, 3032 and in those on these studies, the draft Caring for Australians with who experience a greater initial increase in serum Renal Insufficiency (CARI) guidelines recommend creatinine concentration following the commencement targeting pre-prandial blood glucose levels between of treatment. 14 It is therefore important to avoid 4. 4 and 6. 7 millimoles per liter, and hemoglobin hemoglobin A1c values ≤7% for withdrawal of ACE inhibitors or angiotensin receptor blocker in chronic kidney disease patients all diabetics. 12 However, there is no evidence that who experience an acute rise in plasma creatinine intensive glycaemic control alters renal outcomes concentration of less than 30% that stabilises within once a patient has reached stage 3 chronic kidney disease. the first 2 months of therapy, as these patients are Cessation of smoking the ones who are most likely to derive the greatest renoprotective benefit. 14 Angiotensin converting Although there have been no randomised controlled enzyme inhibitors should be ceased: trials, a large case control study54 has demonstrated if the rise in creatinine level exceeds 30% above that current smoking is a significant, independent the baseline value (consider bilateral renal artery risk factor for more severe proteinuria and clinically stenosis14), or important deterioration in renal function. Former if the serum potassium concentration exceeds 6 smokers were not at increased risk, 54 suggesting millimoles per liter (despite dose reduction, dietary potassium that cessation of smoking may be associated with restriction and concomitant diuretic therapy). a reduction in risk of progressive renal disease. In However, the frequency of this complication in chronic kidney disease retrospective studies of diabetic patients, smoking patients is less than 2%, with the average rise in has been associated with an increased risk of serum potassium levels being of the order of 0. 5 albuminuria and more rapid deterioration of renal millimoles per liter. function. 55, 56 Smoking cessation has been associated A number of randomised controlled studies have with a reduction in albumin excretion55 and renal demonstrated that combining an ACE inhibitor and failure progression in diabetics. 57 angiotensin receptor blocker may result in superior treatment of hypertension, Weight reduction proteinuria and/or kidney failure progression compared with monotherapy. 3339 Obesity has been shown to be a significant, independent risk factor for the development of de Lipid lowering treatments novo CKD5860 and an important accelerant of A number of small randomised controlled trials4047 established chronic kidney disease. 61, 62 It is therefore important to and a meta-analysis48 suggest that the use of statins encourage patients with chronic kidney disease to lose weight through in chronic kidney disease patients with hypercholesterolaemia results in caloric restriction and physical exercise (Table 5). clinically and statistically significant slowing of kidney Dietary protein restriction failure progression.",
    "word_count": 564,
    "char_count": 3828,
    "sentence_count": 22,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 2,
      "total_chunks": 11,
      "position": "3/11",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "kidney failure",
        "nephropathy",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "hemoglobin",
        "dietary protein"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 3,
    "text": "clinically and statistically significant slowing of kidney Dietary protein restriction failure progression. It is presently uncertain whether statins reduce cardiovascular risk in chronic kidney disease patients, but Dietary protein restriction has been shown to this question will be addressed in the next few years result in modest slowing of chronic kidney disease progression by by the Studies of Heart and Renal Protection (SHARP) meta-analyses. 6365 However, this beneficial effect trial. 49 There is insufficient evidence available to define is generally considered to be outweighed by the cholesterol targets in chronic kidney disease patients, but it seems deleterious consequences of nutritional restriction reasonable to adopt the targets recommended by the in chronic kidney disease patients. 24, 66 For these reasons, the CARI National Heart Foundation for patients with increased guidelines recommend a normal dietary protein intake cardiovascular risk (total cholesterol 4. 0 millimoles per liter and (0. 751. 0 g/kg body weight/day). 12 LDL cholesterol 2. 5 millimoles per liter). Correction of anaemia Glycaemic control Limited studies67, 68 have reported that correction Several randomised controlled trials have of uraemic anaemia by erythropoietin slows the demonstrated that intensive blood sugar control progression of chronic kidney disease, although this finding has not significantly reduces the risk of developing been confirmed by other studies. However, patients microalbuminuria, macroalbuminuria and/or overt certainly feel better. 69 Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 4 917 Theme: Chronic kidney disease management update Table 4. Approach to chronic kidney disease patients according to stage chronic kidney disease stage 1 2 3 4 5 Description Kidney damage Kidney damage Moderate Early detection and management of chronic kidney disease complications, such as hyperkalaemia, acidosis and complications hyperphosphataemia, usually become apparent Aside from the fact that the opportunity for renal in stage 4 chronic kidney disease (glomerular filtration rate 1529 milliliters per minute/1. 73 m2). 11 function preservation is greatest when intervention Regular monitoring for all of these complications is instigated early, many of the known complications (at least 3 monthly in stage 3 and monthly in stage of chronic kidney disease such as hypertension, secondary 4) is essential. Recommended treatment goals and hyperparathyroidism, renal osteodystrophy, strategies are listed in Table 5. The NHMRC also anaemia, sleep apnoea, restless legs, cardiovascular recommends immunisation against influenza and disease, and malnutrition, are often already evident invasive pneumococcal disease for patients with by stage 3 (glomerular filtration rate 3059 milliliters per minute/1. 73 m2). 11 Other diabetes and/or chronic kidney failure. 918 3Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 glomerular filtration rate Severe glomerular filtration rate End stage kidney failure normal/ glomerular filtration rate mild glomerular filtration rate glomerular filtration rate (milliliters per minute/1.",
    "word_count": 448,
    "char_count": 3192,
    "sentence_count": 25,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 3,
      "total_chunks": 11,
      "position": "4/11",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "dietary protein",
        "malnutrition",
        "erythropoietin",
        "statins",
        "acidosis",
        "renal osteodystrophy",
        "monitoring"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 4,
    "text": "73 m2) 90 6089 3059 1529 15 or on dialysis Common signs and symptoms Nil Nil Nil or nocturia, mild malaise, Nil or nocturia, malaise, anorexia, Nocturia, mild malaise, anorexia, nausea, anorexia nausea, pruritus, restless legs, dyspnoea vomiting, pruritus, restless legs, dyspnoea Common complications Hypertension Hypertension Hypertension, hyperparathyroidism, Hypertension, hyperparathyroidism, renal Hypertension, hyperparathyroidism, renal renal osteodystrophy, anaemia, osteodystrophy, anaemia, sleep apnoea, restless osteodystrophy, restless legs, cardiovascular disease, malnutrition, sleep apnoea, restless legs, cardiovascular disease, legs, cardiovascular disease, malnutrition, hyperphosphataemia, hyperphosphataemia, acidosis, hyperkalaemia, malnutrition acidosis, hyperkalaemia anaemia, sleep apnoea, paricarditis, GIT bleeding, encephalopathy, neuropathy Clinic assessment blood pressure, weight, blood pressure, weight, blood pressure, weight, blood pressure, weight, volume assessment, urine dipstick blood pressure, weight, volume assessment, urine dipstick volume assessment, volume assessment, volume assessment, urine dipstick urine dipstick urine dipstick Lab assessment UEC, estimated glomerular filtration rate UEC, estimated glomerular filtration rate UEC, estimated glomerular filtration rate UEC, estimated glomerular filtration rate As per monthly blood schedule Glucose Glucose Glucose Glucose specified by renal unit Lipids Lipids Lipids Lipids FBC FBC Iron stores Iron stores calcium/phosphate calcium/phosphate parathyroid hormone (quarterly) parathyroid hormone (quarterly) Echo (annually) Management Diagnosis Diagnosis Diagnosis Diagnosis Dialysis or transplantation Cardiac and kidney Cardiac and kidney Cardiac and kidney Cardiac and kidney risk factor modification (or conservative medical management) risk factor risk factor risk factor Treat complications Treat complications modification modification modification Dialysis education Dialysis access surgery Cardiac and kidney risk factor modification Frequency of clinical 46 months 3 months 13 months Monthly Monthly (shared with renal unit) review Nephrologist referral Consider referral Consider referral Consider referral All patients should be referred to a nephrologist All patients should be referred to a nephrologist if any criteria listed if any criteria listed if any criteria listed in Table 7 are present in Table 7 are present in Table 7 are present blood pressure blood pressure, calcium/phosphate serum calcium and phosphate, cardiovascular disease cardiovascular disease, echo echocardiograph, glomerular filtration rate glomerular filtration rate, estimated glomerular filtration rate estimated glomerular filtration rate (as determined by Cockcroft-Gault or MDRD formulae) FBC full blood count, GIT gastrointestinal tract, parathyroid hormone serum parathyroid hormone level, UEC blood urea electrolytes creatinine Theme: Chronic kidney disease management update Table 4. Approach to chronic kidney disease patients according to stage chronic kidney disease stage 1 2 3 4 5 Description Kidney damage Kidney damage Moderate Medications review severe kidney failure (estimated glomerular filtration rate 30 milliliters per minute; stage 4 or Dosage reduction or cessation of renally excreted 5 chronic kidney disease) medications is generally required once the glomerular filtration rate falls diabetic nephropathy below about 50 milliliters per minute/1. 73 m2. A list of commonly rapidly deteriorating renal function, or prescribed, renally excreted medications requiring features suggestive of an underlying review in chronic kidney disease patients is provided in Table 6. It is also glomerulonephritis (eg. haematuria, casts or important to avoid nephrotoxic medications (Table 6). proteinuria in excess of 1g/day) should be referred to a nephrologist (Table 7). Indications for referral A number of studies7072 have demonstrated The CARI guidelines recommend that patients with: that early referral of patients with severe chronic kidney disease to a Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 4 919 glomerular filtration rate Severe glomerular filtration rate End stage kidney failure normal/ glomerular filtration rate mild glomerular filtration rate glomerular filtration rate (milliliters per minute/1.",
    "word_count": 560,
    "char_count": 4351,
    "sentence_count": 10,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 4,
      "total_chunks": 11,
      "position": "5/11",
      "content_type": "recommendation",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal function",
        "kidney failure",
        "nephropathy",
        "proteinuria",
        "creatinine",
        "urea",
        "calcium",
        "phosphate"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 5,
    "text": "73 m2) 90 6089 3059 1529 15 or on dialysis Common signs and symptoms Nil Nil Nil or nocturia, mild malaise, Nil or nocturia, malaise, anorexia, Nocturia, mild malaise, anorexia, nausea, anorexia nausea, pruritus, restless legs, dyspnoea vomiting, pruritus, restless legs, dyspnoea Common complications Hypertension Hypertension Hypertension, hyperparathyroidism, Hypertension, hyperparathyroidism, renal Hypertension, hyperparathyroidism, renal renal osteodystrophy, anaemia, osteodystrophy, anaemia, sleep apnoea, restless osteodystrophy, restless legs, cardiovascular disease, malnutrition, sleep apnoea, restless legs, cardiovascular disease, legs, cardiovascular disease, malnutrition, hyperphosphataemia, hyperphosphataemia, acidosis, hyperkalaemia, malnutrition acidosis, hyperkalaemia anaemia, sleep apnoea, paricarditis, GIT bleeding, encephalopathy, neuropathy Clinic assessment blood pressure, weight, blood pressure, weight, blood pressure, weight, blood pressure, weight, volume assessment, urine dipstick blood pressure, weight, volume assessment, urine dipstick volume assessment, volume assessment, volume assessment, urine dipstick urine dipstick urine dipstick Lab assessment UEC, estimated glomerular filtration rate UEC, estimated glomerular filtration rate UEC, estimated glomerular filtration rate UEC, estimated glomerular filtration rate As per monthly blood schedule Glucose Glucose Glucose Glucose specified by renal unit Lipids Lipids Lipids Lipids FBC FBC Iron stores Iron stores calcium/phosphate calcium/phosphate parathyroid hormone (quarterly) parathyroid hormone (quarterly) Echo (annually) Management Diagnosis Diagnosis Diagnosis Diagnosis Dialysis or transplantation Cardiac and kidney Cardiac and kidney Cardiac and kidney Cardiac and kidney risk factor modification (or conservative medical management) risk factor risk factor risk factor Treat complications Treat complications modification modification modification Dialysis education Dialysis access surgery Cardiac and kidney risk factor modification Frequency of clinical 46 months 3 months 13 months Monthly Monthly (shared with renal unit) review Nephrologist referral Consider referral Consider referral Consider referral All patients should be referred to a nephrologist All patients should be referred to a nephrologist if any criteria listed if any criteria listed if any criteria listed in Table 7 are present in Table 7 are present in Table 7 are present blood pressure blood pressure, calcium/phosphate serum calcium and phosphate, cardiovascular disease cardiovascular disease, echo echocardiograph, glomerular filtration rate glomerular filtration rate, estimated glomerular filtration rate estimated glomerular filtration rate (as determined by Cockcroft-Gault or MDRD formulae) FBC full blood count, GIT gastrointestinal tract, parathyroid hormone serum parathyroid hormone level, UEC blood urea electrolytes creatinine Theme: Chronic kidney disease management update multidisciplinary renal unit is associated with reduced 12 months before the anticipated commencement rates of kidney failure decline, decreased need for of dialysis and/or kidney transplantation (ie. glomerular filtration rate and duration of hospitalisation, increased likelihood ≤30 milliliters per minute/1. 73 m2). Nevertheless, in spite of this, of permanent dialysis access created before dialysis approximately 30% of chronic kidney disease patients in Australia are onset, reduced initial costs of care following the referred late to nephrologists (ie. within 3 months of commencement of dialysis, increased likelihood of needing to commence kidney replacement therapy). kidney transplantation, and decreased patient morbidity Such late referred patients have markedly reduced and mortality. The CARI guidelines recommend that survival rates on dialysis and are much less likely to patients should be referred to renal units at least receive a kidney transplant. 73 Table 5. Treatment targets for chronic kidney disease patients Parameter Target Treatment Lifestyle factors Cease smoking Lifestyle counselling Smoking body mass index 25 kg/m2 Nutrition WC 102 cm (male), 88 cm (female) Alcohol Dietary salt intake 1 mmol/kg/day Physical activity ≤2 standard glasses alcohol/day ≥30 mins/day physical activity Blood pressure ≤130/85 mmHg ACE inhibitor and/or angiotensin receptor blocker first line lifestyle modification (≤125/75 mmHg if proteinuria 1 g/day or diabetes) Proteinuria ≥50% reduction of baseline value ACE inhibitor and/or angiotensin receptor blocker first line Cholesterol Total 4. 0 millimoles per liter Dietary advice LDL 2.",
    "word_count": 595,
    "char_count": 4624,
    "sentence_count": 10,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 5,
      "total_chunks": 11,
      "position": "6/11",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "proteinuria",
        "creatinine",
        "urea",
        "calcium",
        "phosphate",
        "parathyroid hormone",
        "iron"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 6,
    "text": "0 millimoles per liter Dietary advice LDL 2. 5 millimoles per liter Statins Blood sugar (diabetics) Pre-prandial BSL 4. 46. 7 millimoles per liter Lifestyle modification hemoglobin hemoglobin A1c ≤7. 0% Oral hypoglycaemics Insulin Dietary protein 0. 751. 0 g/kg body weight/day (normal) Dietary advice Anaemia hemoglobin 110120 g/L Correct iron deficiency Erythropoietin/darbepoietin Acidosis bicarbonate 22 millimoles per liter NaHCO3 tablets Hyperkalaemia potassium ≤6. 0 millimoles per liter Dietary advice Diuretics Resonium Cease ACE inhibitor/angiotensin receptor blocker if potassium persistently 6. 0 millimoles per liter Hyperparathyroidism/ phosphate ≤1. 75 millimoles per liter Calcitriol osteodystrophy parathyroid hormone 25 times upper limit of normal Phosphate binders (calcium carbonate, aluminium hydroxide, magnesium trisilicate, sevelamer) Cinacalcet Malnutrition Albumin ≥35 g/L Dietary advice Restless legs Control symptoms Correct iron deficiency Dopaminergic agents Sleep apnoea Prevent apnoeic episodes Weight reduction Avoid central nervous system depressants CPAP therapy (if obstructive pattern) 920 3Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 Theme: Chronic kidney disease management update Table 7. Indications for referral of chronic kidney disease Summary of important points patients to a nephrologist Patients with stages 13 chronic kidney disease are likely to be estimated glomerular filtration rate 30 milliliters per minute/1. 73 m2 (stage 4 or 5 chronic kidney disease) asymptomatic and diagnosis should be actively Rapidly declining kidney function (15% sought in patients with chronic kidney disease risk factors. chronic kidney disease is the strongest known risk factor for cardiovascular disease, such that chronic kidney disease patients are far more likely to die of ischaemic heart disease than to end up on dialysis. ACE inhibitors remain the first line antihypertensive agents in patients with chronic kidney disease. Proven effective interventions include reduction of blood pressure (most important), prescription of an Conclusion ACE inhibitor and/or angiotensin receptor blocker as antiproteinuric agents, Chronic kidney disease is a common, underlowering of serum cholesterol, cessation of smoking, recognised and eminently treatable condition that correction of anaemia and intensive glycaemic affects over 2. 3 million Australians. It is also a major control (in diabetics before the development of risk factor for cardiovascular disease, such that macroalbuminuria). chronic kidney disease patients are far more likely to die of ischaemic Nephrotoxic drugs should be avoided in chronic kidney disease heart disease than to end up on dialysis. General patients. practitioners are the key health care providers for Many commonly prescribed medications are renally patients with chronic kidney disease and need to be aware of: strategies excreted and should have their dosages reduced for modifying the risk of cardiovascular disease and when the glomerular filtration rate falls below 50 milliliters per minute/1. 73 m2. kidney failure progression in chronic kidney disease patients; strategies for detecting and treating complications at each of Conflict of interest: none declared. the various stages of chronic kidney disease; commonly prescribed References medications that are nephrotoxic or require dose 1. Johnson DW, Usherwood T. Automated reporting of glomerular reduction/cessation in chronic kidney disease; and the indications for filtration rate: coming soon to a laboratory near you! Aust Fam nephrologist referral. Physician 2005; 34: 92531. Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 4 921 Table 6. Frequently used drugs that may accumulate in kidney failure or damage the kidneys further Commonly prescribed drugs that need to be reduced in dose or ceased in kidney failure Acetazolamide Aciclovir Colchicine Digoxin Gabapentin Lithium Sotalol Sulphonylureas Metformin (significantly increased risk of lactic acidosis when glomerular filtration rate 50 milliliters per minute/1.",
    "word_count": 575,
    "char_count": 4111,
    "sentence_count": 32,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 6,
      "total_chunks": 11,
      "position": "7/11",
      "content_type": "treatment",
      "content_type_confidence": 10,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "potassium",
        "calcium",
        "phosphate",
        "magnesium",
        "bicarbonate",
        "hemoglobin"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 7,
    "text": "73 m2) Commonly prescribed drugs that can damage kidneys in patients with chronic kidney disease Nonsteroidal anti-inflammatories, COX-2 inhibitors ACE inhibitors and angiotensin 2 receptor antagonists Beware, especially, the triple wammy of nonsteroidal anti-inflammatory drug/COX-2 inhibitor, ACE inhibitor and diuretic Radiographic contrast agents Aminoglycosides in glomerular filtration rate over 3 months) Significant proteinuria 1 g/24 hours Glomerular haematuria Kidney impairment plus hypertension that proves difficult to control Diabetes with kidney impairment or proteinuria/albuminuria Theme: Chronic kidney disease management update 2. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney 9): 3945. damage in Australian adults: The AusDiab kidney study. J Am Soc 23. Lovell HG. Are angiotensin converting enzyme inhibitors useful Nephrol 2003; 14: S1318. for normotensive diabetic patients with microalbuminuria? Oxford: 3. McClellan WM, Knight DF, Karp H, Brown WW. Early detection Cochrane Database of Systematic Reviews, 2000. and treatment of renal disease in hospitalised diabetic and hyperten24. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein sive patients: important differences between practice and published restriction and blood-pressure control on the progression of chronic guidelines. Am J Kidney Dis 1997; 29: 36875. renal disease. Modification of Diet in Renal Disease Study Group. N 4. John R, Webb M, Young A, Stevens physical examination. Unreferred chronic kidney Engl J Med 1994; 330: 87784. disease: a longitudinal study. Am J Kidney Dis 2004; 43: 82535. 25. GISEN Group. Randomised placebo controlled trial of effect of 5. potassium/DOQI clinical practice guidelines for chronic kidney disease: evaluaramipril on decline in glomerular filtration rate and risk of terminal tion, classification, and stratification. Am J Kidney Dis 2002; 39: S1266. renal failure in proteinuric, non-diabetic nephropathy. The GISEN 6. Joint Specialty Committee of the Royal College of Physicians of Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). London and the British Renal Association. Guidelines for identificaLancet 1997; 349: 185763. tion, management and referral of adults with chronic kidney disease. 26. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. London: Department of Health for England, 2005; 203. Renal function and requirement for dialysis in chronic nephropathy 7. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion patients on long term ramipril: REIN follow up trial. Gruppo Italiano predicts cardiovascular and noncardiovascular mortality in general di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in population. Circulation 2002; 106: 177782. Nephropathy. Lancet 1998; 352: 12526. 8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic 27. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. kidney disease and the risks of death, cardiovascular events, and hospiGreater reduction of urinary albumin excretion in hypertensive type talisation. N Engl J Med 2004; 351: 1296305. II diabetic patients with incipient nephropathy by lisinopril than by 9. Weiner DE, Tighiouart H, Amin magnesium, et al. Chronic kidney disease nifedipine. J Hum Hypertens 1996; 10: 18592. as a risk factor for cardiovascular disease and all cause mortality: a 28. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects pooled analysis of community based studies. J Am Soc Nephrol of enalapril in hypertensive NIDDM: role of baseline albuminuria. 2004; 15: 130715. Kidney Int Suppl 1994; 45: S1505. 10. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the 29. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in risk for cardiovascular disease, renal replacement, and death in the type 2 diabetes. N Engl J Med 2004; 351: 194151. United States Medicare population, 1998 to 1999. J Am Soc Nephrol 30. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH.",
    "word_count": 600,
    "char_count": 4033,
    "sentence_count": 61,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 7,
      "total_chunks": 11,
      "position": "8/11",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal function",
        "renal failure",
        "nephropathy",
        "albuminuria",
        "proteinuria",
        "potassium",
        "magnesium",
        "diet"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 8,
    "text": "J Am Soc Nephrol 30. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. 2005; 16: 48995. Long term effect of lisinopril and atenolol on kidney function in 11. Johnson DW. Evidence based guide to slowing the progression of early hypertensive NIDDM subjects with diabetic nephropathy. Diabetes renal insufficiency. Intern Med J 2004; 34: 507. 1997; 46: 11828. 12. Johnson D W, Mathew T, Gillin A, et al. CARI guidelines: Prevention 31. Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood of progression of kidney disease. Sydney, Australian and New Zealand pressure control, and the progression of polycystic kidney disease. Society of Nephrology, 2002. Available at: www. kidney. org. au/cari/ Modification of Diet in Renal Disease Study Group published drafts/new/prevention. html. erratum appears in J Am Soc Nephrol 1995 Oct; 6: 1318. J Am Soc 13. Jafar TH, Schmid CH, Landa M, et al. Angiotensin converting Nephrol 1995; 5: 203747. enzyme inhibitors and progression of nondiabetic renal disease. A 32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiometaanalysis of patient level data. Ann Intern Med 2001; 135: 7387. tensin converting enzyme inhibition on diabetic nephropathy. The 14. Bakris GL, Weir MR. Angiotensin converting enzyme inhibitor assoCollaborative Study Group. N Engl J Med 1993; 329: 145662. ciated elevations in serum creatinine: is this a cause for concern? Arch 33. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect Intern Med 2000; 160: 68593. of converting enzyme inhibitor and losartan in normotensive patients 15. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long term effects of antihywith IgA nephropathy. Am J Kidney Dis 1999; 33: 8516. pertensive agents on proteinuria and renal function. Arch Intern Med 34. Kincaid-Smith P, Fairley potassium, Packham D. Randomised controlled crossover study of the effect on proteinuria and blood pressure of 1995; 155: 107380. adding an angiotensin II receptor antagonist to an angiotensin con16. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antiverting enzyme inhibitor in normotensive patients with chronic renal hypertensive therapy on the kidney in patients with diabetes: a disease and proteinuria. Nephrol Dial Transplant 2002; 17: 597601. meta-regression analysis. Ann Intern Med 1993; 118: 12938. 35. Jacobsen P, Andersen S, Rossing potassium, Hansen BV, Parving HH. Dual 17. Giatras I, Lau J, Levey AS. Effect of angiotensin converting enzyme blockade of the renin-angiotensin system in type 1 patients with diainhibitors on the progression of nondiabetic renal disease: a metabetic nephropathy. Nephrol Dial Transplant 2002; 17: 101924. analysis of randomised trials. Angiotensin-Converting-Enzyme 36. Jacobsen P, Andersen S, Rossing potassium, Jensen BR, Parving HH. Dual Inhibition and Progressive Renal Disease Study Group. Ann Intern blockade of the renin-angiotensin system versus maximal recomMed 1997; 127: 33745. mended dose of ACE inhibition in diabetic nephropathy. Kidney Int 18. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect 2003; 63: 187480. of the angiotensin-receptor antagonist irbesartan in patients with 37. Rossing potassium, Christensen PK, Jensen BR, Parving HH. Dual blockade nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851: 60. of the renin-angiotensin system in diabetic nephropathy: a randomised 19. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen double blind crossover study. Diabetes Care 2002; 25: 95100. S, Arner P. The effect of irbesartan on the development of dia38. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled betic nephropathy in patients with type 2 diabetes. N Engl J Med trial of dual blockade of renin-angiotensin system in patients with 2001; 345: 8708. hypertension, microalbuminuria, and non-insulin dependent diabetes: 20.",
    "word_count": 594,
    "char_count": 3884,
    "sentence_count": 66,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 8,
      "total_chunks": 11,
      "position": "9/11",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "kidney function",
        "renal function",
        "nephropathy",
        "proteinuria",
        "creatinine",
        "potassium",
        "serum creatinine",
        "diet",
        "dietary protein",
        "insulin"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 9,
    "text": "Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on the candesartan and lisinopril microalbuminuria (CALM) study. BMJ renal and cardiovascular outcomes in patients with type 2 diabetes and 2000; 321: 14404. nephropathy. N Engl J Med 2001; 345: 8619. 39. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura 21. Weidmann P, Boehlen LM, de Courten M. Effects of different T. Combination treatment of angiotensin-II receptor blocker and antihypertensive drugs on human diabetic proteinuria. Nephrol Dial angiotensin converting enzyme inhibitor in non-diabetic renal Transplant 1993; 8: 5824. disease (COOPERATE): a randomised controlled trial. Lancet 22. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of dif2003; 361: 11724. ferent antihypertensive drugs in human diabetic nephropathy: an 40. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol lowerupdated meta-analysis. Nephrol Dial Transplant 1995; 10(Suppl ing therapy may retard the progression of diabetic nephropathy. 922 3Reprinted from Australian Family Physician Vol. 34, No. 11, November 2005 Theme: Chronic kidney disease management update Diabetologia 1995; 38: 6049. damage. Pathobiology 2001; 69: 1138. 41. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats 63. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow proeffects of dietary protein restriction on the rate of decline in renal gression of microalbuminuria in patients with non-insulin-dependent function. Am J Kidney Dis 1998; 31: 95461. diabetes mellitus? Eur J Clin Invest 1997; 27: 9971002. 64. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The 42. Thomas ME, Harris KP, Ramaswamy C, et al. Simvastatin therapy for effect of dietary protein restriction on the progression of diabetic hypercholesterolemic patients with nephrotic syndrome or significant and nondiabetic renal diseases: a meta-analysis. Ann Intern Med proteinuria. Kidney Int 1993; 44: 11249. 1996; 124: 62732. 43. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and 65. Fouque D, Laville M, Boissel JP, Chifflet R, Labeeuw M, Zech PY. renal function during simvastatin treatment in diabetic nephropathy. Controlled low protein diets in chronic renal insufficiency: metaDiabetologia 1992; 35: 44751. analysis. BMJ 1992; 304: 21620. 44. Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic 66. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid Smith syndrome. Kidney Int 1999; 56: S1136. PS. The effect of protein restriction on the progression of renal insuf45. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospecficiency. N Engl J Med 1989; 321: 17737. tive study of the effects of atorvastatin on proteinuria and progression 67. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man of kidney disease. Am J Kidney Dis 2003; 41: 56570. NK. Beneficial influence of recombinant human erythropoietin 46. Imai Y, Suzuki H, Saito T, Tsuji I, Abe potassium, Saruta T. The effect therapy on the rate of progression of chronic renal failure in predialysis of pravastatin on renal function and lipid metabolism in patients patients. Nephrol Dial Transplant 2001; 16: 30712. with renal dysfunction with hypertension and hyperlipidemia. 68. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Pravastatin and Renal Function Research Group. Clin Exp Hypertens Sakai O. Reversal of anemia by erythropoietin therapy retards the 1999; 21: 134555. progression of chronic renal failure, especially in nondiabetic patients. 47. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of Nephron 1997; 77: 17685. pravastatin on loss of renal function in people with moderate chronic 69. Revicki DA, Brown RE, Feeny DH, et al. Health related quality renal insufficiency and cardiovascular disease.",
    "word_count": 588,
    "char_count": 3844,
    "sentence_count": 63,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 9,
      "total_chunks": 11,
      "position": "10/11",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "renal function",
        "renal failure",
        "nephropathy",
        "nephron",
        "proteinuria",
        "potassium",
        "dietary protein",
        "erythropoietin",
        "insulin"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 10,
    "text": "Revicki DA, Brown RE, Feeny DH, et al. Health related quality renal insufficiency and cardiovascular disease. J Am Soc Nephrol of life associated with recombinant human erythropoietin therapy 2003; 14: 160513. for predialysis chronic renal disease patients. Am J Kidney Dis 48. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the pro1995; 25: 54854. gression of renal disease: a meta-analysis. Kidney Int 2001; 59: 2609. 70. Churchill diabetic nephropathy. An evidence based approach to earlier initiation of 49. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). dialysis. Am J Kidney Dis 1997; 30: 899906. Kidney Int Suppl 2003; S20710. 71. Binik YM, Devins GM, Barre physical examination, et al. Live and learn: patient educa50. The Diabetes Control and Complications Trial/Epidemiology of tion delays the need to initiate renal replacement therapy in end stage Diabetes Interventions and Complications Research Group. renal disease. J Nerv Ment Dis 1993; 181: 3716. Retinopathy and nephropathy in patients with type 1 diabetes four 72. Curtis BM, Ravani P, Malberti F, et al. The short and long term years after a trial of intensive therapy. N Engl J Med 2000; 342: 3819. impact of multi-disciplinary clinics in addition to standard nephrology 51. Barbosa J, Steffes MW, Sutherland DE, Connett JE, Rao KV, Mauer care on patient outcomes. Nephrol Dial Transplant 2005; 20: 14754. SM. Effect of glycemic control on early diabetic renal lesions. A 5-year 73. Cass A, Cunningham J, Snelling P, Ayanian JZ. Late referral to a randomised controlled clinical trial of insulin dependent diabetic nephrologist reduces access to renal transplantation. Am J Kidney Dis kidney transplant recipients. JAMA 1994; 272: 6006. 2003; 42: 10439. 52. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomised prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 10317. 53. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 83753. 54. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000; 57: 20729. 55. Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265: 6147. 56. Stegmayr B, Lithner F. Tobacco and end stage diabetic nephropathy. BMJ Clin Res Ed 1987; 295: 5812. 57. Sawicki patient, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 12631. 58. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in ultrasound adults. Ann Intern Med 2004; 140: 16774. 59. Fox CS, Larson magnesium, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new onset kidney disease in a community based population. JAMA 2004; 291: 84450. 60. Tozawa M, Iseki potassium, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 95662. 61. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 7207. 62. Sasatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity Email: afpracgp. org. au AFP associated with hypertension or hyperlipidemia accelerates renal Reprinted from Australian Family Physician Vol. 34, No.",
    "word_count": 597,
    "char_count": 3813,
    "sentence_count": 75,
    "metadata": {
      "source_file": "200511johnson.pdf",
      "extraction_date": "2025-11-21T14:30:09.803510",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "dialysis",
        "kidney function",
        "renal",
        "nephrology",
        "albuminuria"
      ],
      "chunk_index": 10,
      "total_chunks": 11,
      "position": "11/11",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "nephropathy",
        "nephritis",
        "albuminuria",
        "proteinuria",
        "potassium",
        "magnesium",
        "erythropoietin",
        "insulin",
        "dialysis"
      ],
      "entity_count": 10
    }
  }
]